Local immune modulation for beta cell replacement therapy in type 1 diabetes

1 型糖尿病 β 细胞替代疗法的局部免疫调节

基本信息

  • 批准号:
    10596656
  • 负责人:
  • 金额:
    $ 48.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT The objective of this project is to induce localized immune tolerance to transplanted human beta cells derived from renewable stem cell sources as a treatment for type 1 diabetes. We will test our approach to prevent immune rejection of grafted human stem cell derived beta cells in diabetic mice with elements of human immune systems. In addition, we seek to explain the detailed biological mechanisms by which the therapy works by conducting in vitro studies using islet- reactive human T cells. Recent advances in the generation of stem cell derived beta-like cells (sBCs) have raised the possibility of providing a renewable source of functional beta cells for transplantation, effectively overcoming the severe shortage of human donor islets. We have generated simplified culture conditions that accurately and efficiently generate unlimited quantities of glucose-responsive insulin-expressing beta cells in vitro. The stem cell derived beta cells generated have already been used successfully for beta cell replacement therapy in animal models. By combining cell engineering with biomaterials engineering to display negative regulators of immunity (e.g. programmed death-ligand 1, PD-L1; and tumor necrosis factor (TNF)- related apoptosis-inducing ligand, TRAIL), we will functionalize stem cell derived beta cells (sBCs) to counter autoimmunity upon transplantation. A major strength of our approach is that the immunotherapy is strongly localized to grafted beta cells, which increases specificity and avoids the negative side effects of systemic immunotherapy. We hypothesize that stem cell derived human pseudo islets transplanted with PD-L1 and/or TRAIL will be resistant to autoimmune destruction and exhibit enhanced engraftment / survival in an in vivo model of beta cell graft rejection using humanized mice. Our strategy will induce localized tolerance to beta cell antigens while simultaneously promoting sBC graft vascularization.
项目摘要/摘要 该项目的目标是诱导对移植的人的局部免疫耐受。 来自可再生干细胞来源的细胞用于治疗1型糖尿病。我们将测试 我们预防糖尿病患者移植的人干细胞来源的β细胞免疫排斥反应的方法 具有人类免疫系统成分的小鼠。此外,我们还试图解释详细的 该疗法的生物学机制是通过使用胰岛进行体外研究- 反应性人类T细胞。干细胞来源的β-样细胞的生成研究进展 (SBCs)已经提出了为以下目的提供可再生的功能β细胞来源的可能性 移植,有效地克服了人类供体胰岛严重短缺的问题。我们有 生成简化的培养条件,准确高效地生成无限 体外培养的葡萄糖反应性胰岛素表达的β细胞数量。干细胞衍生的贝塔 所产生的细胞已经成功地用于动物的β细胞替代治疗 模特们。通过将细胞工程和生物材料工程相结合来展示负片 免疫调节剂(如程序性死亡-配体1,PD-L1;和肿瘤坏死因子(TNF)- 相关的凋亡诱导配体(TRAIL),我们将使干细胞来源的β细胞(SBCs)功能化 以对抗移植后的自身免疫。我们方法的一个主要优点是 免疫治疗强烈局限于移植的β细胞,这增加了特异性并避免了 全身免疫治疗的负面副作用。我们假设干细胞来源于 移植PD-L1和/或TRAIL的人假性胰岛对自身免疫具有抵抗力 体内β细胞移植模型中的破坏和增强的植入/存活 用人源化的小鼠进行排斥反应。我们的策略将诱导对β细胞抗原的局部耐受 同时促进SBC移植物的血管化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edward Phelps其他文献

Edward Phelps的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edward Phelps', 18)}}的其他基金

Local immune modulation for beta cell replacement therapy in type 1 diabetes
1 型糖尿病 β 细胞替代疗法的局部免疫调节
  • 批准号:
    10713402
  • 财政年份:
    2022
  • 资助金额:
    $ 48.73万
  • 项目类别:
Local immune modulation for beta cell replacement therapy in type 1 diabetes
1 型糖尿病 β 细胞替代疗法的局部免疫调节
  • 批准号:
    10632621
  • 财政年份:
    2022
  • 资助金额:
    $ 48.73万
  • 项目类别:
Mechanism and dynamics of islet GABA signaling
胰岛 GABA 信号传导机制和动力学
  • 批准号:
    10318211
  • 财政年份:
    2021
  • 资助金额:
    $ 48.73万
  • 项目类别:
Mechanism and dynamics of islet GABA signaling
胰岛 GABA 信号传导机制和动力学
  • 批准号:
    10540311
  • 财政年份:
    2021
  • 资助金额:
    $ 48.73万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.73万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了